Clinical trials: PD-1
Gastric Cancer
Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer（RC48-C018）
This trial is a multi-center, open, single-arm, superior phase II clinical study.
- Trial name
- NCT05113459
- Testing
- Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Guoxin Li
Parkinson Disease, MSA - Multiple System Atrophy
Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease
Clinical diagnosis of Parkinson's disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB) is challenging, especially in the early stages.
- Conditions
- Parkinson Disease, MSA - Multiple System Atrophy, Lewy Body Dementia (LBD), Neurodegenerative Disease
- Trial name
- EXTRAORDINARY (NCT06846658)
- Where
- 3 sites in Italy
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Parkinson Disease, Dementia With Lewy Bodies
Optimization of Morphomer-based Alpha-synuclein PET Tracers
The aim of the project is to develop the first alpha-synuclein (a-syn)-specific PET tracer. The research phase will exploit ACI's proprietary MorphomerTM library and extensively optimized screening workflow.
- Conditions
- Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy, Corticobasal Degeneration
- Trial name
- NCT05067192
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Sepsis
PD-1/PD-L1 Pathway Study on Septic Patients
The investigators want to identify that whether PD-1/PD-L1 pathway will change in human sepsis, and whether PD-1/PD-L1 pathway play an important role in sepsis induced immunosuppression.
- Trial name
- NCT01161745
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Changhai Hospital
Positron-Emission Tomography, Alpha Synuclein Pathology
Study of 18F-0502B PET Imaging Targeting α-synuclein in the Diagnosis of α-synuclein-related Diseases
To explore the diagnostic value of 18F-0502B brain imaging for α-Syn protein-related diseases in patients with PD. To evaluate the imaging range of α-Syn protein density in patients with α-Syn protein-related diseases and to…
- Trial name
- NCT05757804
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
Parkinson Disease, Gaucher Disease
Biomarker Analysis for GBA Associated Parkinson's Disease
The primary aim of the study is to conclusively demonstrate the possibility of using the following molecules, α-Synuclein, LRRK2 and Parkin individually or in combination as biomarkers for Parkinson's disease (PD) progression in…
- Trial name
- NCT03811496
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Lysosomal and Rare Disorders Research and Treatment Center, Inc.
RT-QuIC
Plasma a-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Neurodegeneration Disease
Synuclein disease, also known as Synucleinopathies, is a general term for a class of degenerative diseases. It mainly includes Parkinson's disease (PD), Dementia with lewy bodies (DLB), Multiple system atrophy (MSA) and so on.
- Trial name
- NCT07498686
- Where
- 2 sites in China
- Volunteers
- 458 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Healthy Volunteers
A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects
The purpose of this study is to determine the safety, tolerability and blood levels of orally administered anle138b in healthy subjects.
- Trial name
- NCT04208152
- Testing
- anle138b
- Where
- United Kingdom
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
NSCLC
18F-FDG PET/CT to Evaluate pD-1 Monoclonal Antibody With First-line Chemotherapy in Advanced NSCLC
This study is a diagnostic study. Subjects were enrolled from clinical stage IIIB or IV NSCLC patients who received standard first-line chemotherapy combined with PD-1 monoclonal antibody immunotherapy and received 18F-FDG PET/CT…
- Trial name
- NCT04996927
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Recurrent Human Papillomavirus Type 16 Associated Cancer
TA-CIN Vaccine With Anti-PD-1 Therapy in Recurrent HPV16-associated Cancers
The primary to assess the safety and tolerability of TA-CIN and anti-PD-1 therapy in patients with recurrent HPV16-associated cancers and to assess the feasibility of IT injection of TA-CIN in patients with recurrent…
- Trial name
- NCT05132803
- Testing
- HPV 16 TA-CIN
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chordoma, Chemotherapy Effect
Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma
This phase II trial studies how well Camrelizumab combined with Apatinib work in treating participants with chordoma that has spread to other places in the body, which may interfere with the ability of tumor cells to grow and…
- Trial name
- NCT06140732
- Testing
- camrelizumab and apatinib
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT.
- Conditions
- Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
- Trial name
- NCT05595447
- Testing
- Brentuximab Vedotin 50 MG [Adcetris]
- Where
- Mexico
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hospital Regional de Alta Especialidad del Bajio
Parkinson's Disease
Systemic Synuclein Sampling Study (S4)
The purpose of this study is to measure alpha-synuclein in peripheral body tissues and fluids in Parkinson's disease (PD). This may help in developing better treatments for PD patients in the future.
- Trial name
- S4 (NCT02572713)
- Testing
- Biofluid samplings, Tissue samplings, DaTSCAN™
- Where
- 6 sites in United States, Canada
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Michael J. Fox Foundation for Parkinson's Research
Multiple System Atrophy
Insulin Resistance in Multiple System Atrophy
Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder. The pathologic hallmark is the accumulation of aggregated alpha-synuclein in oligodendrocytes forming glial cytoplasmic inclusions.
- Trial name
- IRAMS (NCT04250493)
- Testing
- Homeostasis Model Assessment of insulin resistance (HOMA), MOntreal Cognitive Assessment (MoCA), Clinical characteristics of AMS patients
- Where
- France
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Immunotherapy, Refractory Leukemia
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML
This is an single center, single arm, phase 3 study to evaluate efficacy and safety of PD-1 Inhibitor combined with DNA methyltransferase inhibitor Azacytidine and HAG regimen for patients with relapsed and refractory acute…
- Conditions
- Immunotherapy, Refractory Leukemia, Relapsed Adult AML, Acute Myeloid Leukemia
- Trial name
- NCT04722952
- Testing
- Visilizumab
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Soochow University
Lewy Body Disease
Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease
The goal of the study is to assess if learning one's Lewy Body Dementia (LBD) biomarker test result impacts longitudinal psychosocial and behavioral responses and to identify factors that moderate and mediate these outcomes.
- Trial name
- NCT07646652
- Testing
- LBD Biomarker Education and Disclosure
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Stanford University
AML (Acute Myelogenous Leukemia)
Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade
The combination of azacitidine and venetoclax is currently considered a therapeutic strategy innovative in AML through the addition of new compounds (triplet therapies), including inhibitors of the immune checkpoint inhibitors.
- Trial name
- NCT06874257
- Testing
- Laboratory tests and in vitro studies
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Parkinson Disease
FoxBioNet Pilot Project: SAVE (Synuclein Assay Validation Effort)
The overall objective of this study is to compare the performance of available oligomeric and phosphorylated a-synuclein assay in cerebrospinal fluid and blood.
- Trial name
- SAVE001 (NCT03170063)
- Testing
- Procedure/Surgery: Biofluid samplings
- Where
- 5 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Michael J. Fox Foundation for Parkinson's Research
Endometrial Carcinoma, Cervix Carcinoma
GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab
The aim of this study is to investigate the safety and the clinical activities of NP137 when combined with pembrolizumab and/or chemotherapies in patients with advanced/metastatic gynecological cancers (2 types: endometrial…
- Trial name
- GYNET (NCT04652076)
- Testing
- NP137, Pembrolizumab, Paclitaxel
- Where
- 15 sites in France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- NETRIS Pharma
Healthy Male Adults Participants
A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Participations
This study is to evaluate the pharmacokinetic (PK) similarity of AK104 (an anti-PD-1/CTLA-4 bispecific antibody) from the proposed new manufacturing site and the approved original site in healthy male participants.
- Trial name
- NCT07619001
- Testing
- AK104 (New Site), AK104 (Original Site)
- Where
- China
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- Akeso